Immuneering Q2 FY26 net loss narrows to $17.3 million; R&D expense rises to $14 million
IMRX•Program update and outlook
- The Phase 3 MAPKeeper 301 trial is underway with patients being dosed; over 30 study locations have been posted.
- The company maintained its outlook for cash runway into 2029 and reiterated mid-2028 topline readout timing for MAPKeeper 301.
Q2 results and cash position
- Immuneering posted a Q2 net loss attributable to common stockholders of $17.3 million, or $0.27 per share, narrowing from $14.4 million, or $0.40, a year earlier.
- R&D expense rose to $14 million from $10.5 million year-ago; G&A increased to $5 million from $4.3 million.
- Cash, cash equivalents, and marketable securities totaled $182.7 million at June 30, down from $217 million at Dec. 31.
